CO6290702A2 - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos - Google Patents

Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Info

Publication number
CO6290702A2
CO6290702A2 CO10102866A CO10102866A CO6290702A2 CO 6290702 A2 CO6290702 A2 CO 6290702A2 CO 10102866 A CO10102866 A CO 10102866A CO 10102866 A CO10102866 A CO 10102866A CO 6290702 A2 CO6290702 A2 CO 6290702A2
Authority
CO
Colombia
Prior art keywords
replicate
alfavirus
recombinants
mosquitoes
attacked
Prior art date
Application number
CO10102866A
Other languages
English (en)
Spanish (es)
Inventor
Scott C Weaver
Iiya Frolov
Elena Frolova
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CO6290702A2 publication Critical patent/CO6290702A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CO10102866A 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos CO6290702A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24

Publications (1)

Publication Number Publication Date
CO6290702A2 true CO6290702A2 (es) 2011-06-20

Family

ID=41217313

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10102866A CO6290702A2 (es) 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Country Status (15)

Country Link
US (3) US8426188B2 (https=)
EP (2) EP3085787B1 (https=)
JP (1) JP5758632B2 (https=)
KR (2) KR101668849B1 (https=)
CN (1) CN102083986B (https=)
AU (1) AU2009238667A1 (https=)
CA (2) CA2910235C (https=)
CO (1) CO6290702A2 (https=)
IL (2) IL207167A (https=)
MX (3) MX378503B (https=)
MY (1) MY178870A (https=)
NZ (2) NZ603790A (https=)
SG (2) SG187513A1 (https=)
WO (1) WO2009131604A2 (https=)
ZA (1) ZA201005943B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460913B2 (en) * 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
KR101668849B1 (ko) 2008-01-24 2016-10-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
BR112015006840A2 (pt) 2012-09-27 2017-11-21 Res Found Dev vírus chikungunya atenuado
AP2015008733A0 (en) 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
PE20190178A1 (es) * 2016-03-31 2019-02-01 Takeda Vaccines Inc Constructos de alfavirus vivo atenuado y metodos y usos de los mismos
US11090384B2 (en) * 2016-05-27 2021-08-17 Griffith University Arthrogenic alphavirus vaccine
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
US20210268098A1 (en) * 2018-08-03 2021-09-02 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
US7442381B2 (en) 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
EP1658744A4 (en) 2004-07-30 2006-09-27 Research In Motion Ltd METHOD AND SYSTEM FOR COORDINATING THE PARAMETERS OF A DEVICE BETWEEN A COMMUNICATIONS CLIENT AND HOST DEVICE
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
KR101668849B1 (ko) 2008-01-24 2016-10-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Also Published As

Publication number Publication date
CN102083986A (zh) 2011-06-01
AU2009238667A1 (en) 2009-10-29
MX378503B (es) 2025-03-11
EP3085787B1 (en) 2020-10-28
NZ603790A (en) 2014-08-29
US20170240919A1 (en) 2017-08-24
CN102083986B (zh) 2014-06-18
US9580690B2 (en) 2017-02-28
US20140010841A1 (en) 2014-01-09
MX2019010530A (es) 2019-10-15
NZ587502A (en) 2012-12-21
EP2250269B1 (en) 2016-03-16
ZA201005943B (en) 2011-04-28
JP2011523347A (ja) 2011-08-11
EP2250269A2 (en) 2010-11-17
MX2010007989A (es) 2010-12-21
EP2250269A4 (en) 2012-01-04
EP3085787A1 (en) 2016-10-26
US20110052634A1 (en) 2011-03-03
SG10201606111XA (en) 2016-09-29
KR101913790B1 (ko) 2018-12-28
KR20160124255A (ko) 2016-10-26
KR101668849B1 (ko) 2016-10-24
JP5758632B2 (ja) 2015-08-05
KR20100106599A (ko) 2010-10-01
IL207167A0 (en) 2010-12-30
US10533186B2 (en) 2020-01-14
WO2009131604A2 (en) 2009-10-29
IL232032A0 (en) 2014-05-28
SG187513A1 (en) 2013-02-28
CA2910235A1 (en) 2009-10-29
MX367792B (es) 2019-09-05
US8426188B2 (en) 2013-04-23
CA2910235C (en) 2021-07-06
WO2009131604A3 (en) 2009-12-23
IL207167A (en) 2014-04-30
CA2713165A1 (en) 2009-10-29
MY178870A (en) 2020-10-21
CA2713165C (en) 2015-12-29

Similar Documents

Publication Publication Date Title
CO6290702A2 (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
PA8815301A1 (es) Ido5 antagonistas de pcsk9
UY37563A (es) Aislados de bacillus y usos de los mismos
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX2024008058A (es) Adenovirus modificados.
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
CO6761348A2 (es) Compuestos antivirales
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
CO6420394A2 (es) Estructura tipo lamina insecticida para proteger seres humanos y animales domesticos
CR20120052A (es) Polipéptidos del factor ix modificados y usos de los mismos
CL2013000505A1 (es) Estructura fibrosa fijada y/o estabilizada de un material fibroso asi como un agente para su fijacion y estabilizacion, donde dicho agente es al menos un copoliester estadistico formado por: acido tereftalico, acido isoftalico, butanodiol, dietilenglicol, trietilenglicol; metodo de fabricacion; material compuesto de resina-fibra; y uso de dicha estructura.
MX2020005235A (es) Celula humana transformada y uso de la misma.
AR090606A1 (es) Composicion pesticida
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
CR20140040A (es) Compuestos de antranilamida y sus usos como plaguicidas
WO2012065105A3 (en) Chimeric flavivirus vaccines
CR20140041A (es) Compuestos de antranilamida y sus usos como plaguicidas
BR112015011254A2 (pt) Utilização de um composto constituído por uma unidade de polifluorobenzilo contra pragas resistentes a inseticidas
BR112015032388A8 (pt) glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições
BR112015013071A8 (pt) solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida
AR083215A1 (es) Combinacion sinergica de abamectina y bifentrina, su proceso de preparacion y uso, y metodo utilizando la misma
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
BR112013013960A8 (pt) Composi%c3%87%c3%95es de vacinas de mal%c3%81ria, polipept%c3%8ddeos, fragmentos do mesmo, mol%c3%89culas de %c3%81cido nucleico, e usos destes
UY31649A1 (es) Cierto nitrógeno que contiene entidades químicas bicíclicas para tratar infecciones virales.

Legal Events

Date Code Title Description
FG Application granted